In our sample, patient 11 showed a recurrence that did not present the BRCA1 mutation that was present at diagnosis, possibly due to maintenance treatment with a PARP inhibitor, with an increase in cfDNA, possibly at the expense of the tumour clone with the TP53 mutation. The gene discussed is TP53; the disease is neoplasm.